BRIEF—Verastem CEO to step down

Robert Forrester will resign as chief executive and president of Verastem Oncology.

Dan Paterson has been appointed to president and chief operating officer and a search has begun for a succesor to the CEO position.

Mr Paterson will be supported in his role by chief financial officer Rob Gagnon, whose role is being expanded to include chief business officer.

Lead director Michael Kauffman said: “We remain confident in the growth potential of Copiktra (duvelisib) and we intend to hire a CEO with commercial expertise who will build on the foundation that Robert has established and execute on our ambitious goals for the future.”